Business Categories Reports Podcasts Events Awards Webinars
Contact My Account About

Verlinvest Acquires Significant Minority Stake in Cible Skin

Published February 8, 2024
Published February 8, 2024
Cible Skin

Cible Skin has received a significant minority investment from Verlinvest, an international, family-backed investment firm. 

WHO: French Cible Skin was founded in 2015 by pharmaceutical doctor Raphaël Aknin and entrepreneur Jean Ginefri. The brand has 12 facial products based on its patented immuno-cosmetic approach, which claims to boost the immune system of skin cells to protect, regenerate, and repair the skin informed by skin immunity techniques Aknin developed while researching cancer. 

The brand also has a 6,460-square-foot flagship clinic in Paris' eighth arrondissement called La Maison Cible Skin. Treatments incorporate high-tech machines from South Korea, Japan, and Germany for diagnoses and to track skin’s progress.

Established in 1995, Verlinvest is an international, family-backed investment firm with offices in Brussels, London, New York, Mumbai, and Singapore. It focuses on the consumer goods, health, consumer technology, and lifestyle categories deploying patient, permanent capital to build businesses for the long-term. Investments are made across three core strategies: growth, platform, and venture.

Verlinvest’s portfolio includes beauty and wellness brands Faceland, Juicy Chemistry, Jean D’Estrées,, K-Beauty brand Yepoda, and personalized supplements company Cuure.

WHY: The investment will accelerate international growth in markets such as Europe, China, the US, and South America. It will also support the development of new products and treatments based on its patented immune-cosmetic approach.

IN THEIR OWN WORDS: Cécile Chevallier, Principal at Verlinvest, said, “We truly believe that Cible Skin addresses what consumers are looking for today, which is one, uniqueness, and two, experience. Those qualities are also manifest in the brand’s products and treatments."


  • Verlinvest has taken a significant minority stake in Cible Skin. The financial terms of the deal were not disclosed.

2 Article(s) Remaining

Subscribe today for full access